Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Abstract: An amino dithioperacid thioester compound, a preparation method therefor, and use thereof. The structural formula of compound is as shown in formula I: wherein m=1-11, X is a nitrogen-containing aliphatic heterocyclic ring, and a nitrogen atom in the aliphatic heterocyclic ring is connected to a carbon atom of a thiocarbonyl group. The compounds disclosed by the invention are found to be capable of relieving muscular atrophy and lipolysis caused by cancer cachexia through in-vivo and in-vitro experiments. The compounds are also capable of obviously relieving weight and food intake reduction caused by cancer cachexia in animal experiments, so that the carbamo(dithioperoxo)thioates compounds have the effect on resisting cancer cachexia, can be applied to the treatment of cancer cachexia and related diseases, and become one kind of ideal cancer cachexia treatment medicament.

Abstract: The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

Abstract: A compound represented by formula (I) or a salt thereof, and a herbicide containing at least one selected from the group consisting of the compounds described above as an active ingredient. In formula (I), R1 represents a substituted or unsubstituted C1 to C6 alkyl group, or the like, R2 represents H, a substituted or unsubstituted C1 to C6 alkyl group, or the like, R3 represents H, a substituted or unsubstituted C1 to C6 alkyl group, or the like, R4 represents a halogeno group, a substituted or unsubstituted C1 to C6 alkyl group, or the like, R5 represents H or a halogeno group, R6 represents H or a halogeno group, A represents a substituted or unsubstituted C1 to C4 alkylene group, a substituted or unsubstituted C2 to C3 alkenylene group, or a C1 to C2 alkyleneoxy C1 to C2 alkylene group, X1 represents O or a sulfonyl group, X2 represents O, a sulfenyl group, or the like, m represents 0 or 1, n represents 0 or 1, and m+n=1 or 2, and when A is a substituted or unsubstituted methylene group, m+n=2.

Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

Abstract: Provided are a new class of hydrazone amide derivatives and the use thereof in the preparation of anti-osteoporosis drugs, wherein the structural formula of the hydrazone amide derivative is as shown in formula (I), and same are a new class of compounds with an anti-osteoporosis effect.

Abstract: A method for purifying a waste N-methyl-2-pyrrolidone (NMP) mixed solution according to an embodiment of the present disclosure includes using a base. The base according to an embodiment may be NaBH4. N-methylsuccinimide and ?-butyrolactone are simultaneously removed, and high-purity NMP can be recovered by applying a base to the waste NMP mixed solution.

Abstract: Disclosed is a method of preparing glufosinate, and specifically a method of preparing glufosinate represented by formula (I) or its salt or enantiomer, or a mixture of its enantiomers in any ratio, comprising a step of hydrolyzing a compound of formula (III) to generate a compound of formula (I). Due to a distinctive reaction mechanism adopted in the method of the present disclosure, a halogenated hydrocarbon by-product in the Michaelis-Arbuzov reaction can be avoided and thus the destructive impact of the halogenated hydrocarbon by-product on ozone in the aerosphere can be prevented. Accordingly, the equipment and engineering investments required for the separation, purification, and collection of the foregoing by-product are eliminated, and the potential environmental and safety hazards brought by the foregoing by-product are also avoided.

Abstract: This disclosure relates generally to cannabinoid derivatives, pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives.

Abstract: Provided is a heterocyclic compound of Chemical Formula 1: wherein: X is O or S; Y1, Y2 and Y3 are each independently CH or N, provided that at least one is N; L1 and L2 are each independently a direct bond, a substituted or unsubstituted C6-60 arylene, or a substituted or unsubstituted C5-60 heteroarylene containing at least one of N, O and S; and Ar is a substituted or unsubstituted C6-60 aryl, and Ar2 and Ar3 are each independently a substituted or unsubstituted C6-60 aryl or a C5-60 heteroaryl containing at least one of N, O and S, provided that when all of Ar1, Ar2 and Ar3 are a substituted or unsubstituted C6-60 aryl, any one of Ar1, Ar2 and Ar3 is substituted with 4 or more deuteriums; and an organic light emitting device including the same.

Abstract: The present disclosure provides methods of preparing a compound of Formula (I): wherein R1, R2, and R3 are as defined as set forth in the application. In one embodiment, a compound of Formula (I) is prepared in >95% chemical purity and >95% enantiomeric excess.

Abstract: Disclosed herein are methods of crystallizing the compound of Formula I, as well as crystalline forms thereof. Crystalline forms of Formula I disclosed include the TBME solvate crystalline form, toluene solvate crystalline form, ethanol solvate crystalline form, THF solvate crystalline form, EtOAc solvate crystalline form, acetone solvate crystalline form and crystalline Form C.

Abstract: Disclosed is crystal form I of compound (S)—N-[5-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrole-1-yl]acetamide.

Abstract: Provided is an industrially advantageous method for producing a methylene disulfonate compound easily and inexpensively using fewer raw materials. The method for producing a methylene disulfonate compound of the present invention comprises step A of reacting at least one alkanesulfonic acid compound and sulfur trioxide in the presence of at least one member selected from the group consisting of a sulfoxide compound and a sulfone compound to thereby obtain reactant A comprising an alkanedisulfonic acid compound, and step B of reacting reactant A obtained in step A and a formaldehyde compound in the presence of sulfur trioxide to thereby obtain a methylene disulfonate compound.

Abstract: The present invention relates to a compound represented by general formula (I) (in the formula (I), X represents a methyl group or a halogen atom; R1 to R14 each independently represent a hydrogen atom, a halogen atom, a cyano group, an optionally substituted alkyl group having 1 to 8 carbon atoms, or an optionally substituted aromatic hydrocarbon group having 6 to 12 carbon atoms; Bm? represents a polyoxometalate anion; m represents an integer of 1 to 20; n represents an integer of 1 to 20, provided that n is determined such that the charge of the whole formula (I) becomes zero).

Abstract: The present invention is directed to styryl quinolinium compounds, a process for their synthesis and their use for selective nucleoli staining in cells, preferably in living cells and for imaging rRNA.

Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Abstract: The present invention provides compounds, compositions thereof, and processes for preparing same.

Abstract: The present invention relates to a compounds of formula I R1-(A1-Z1)r—B1—ZL-A2-(Z3-A3)s-G??(I) in which the occurring groups and parameters have the meanings given in claim 1, to the use thereof for the formation of molecular layers, in particular self assembled monolayers, to a process for the fabrication of a switching element for memristive devices comprising said molecular layers and to a memristic device comprising said switching element.